Stock Events

Stock Events

Immutep Limited 

€0.017500
75
-€0.00-2.78%Thursday 06:06

Statistics

Day High
0.0175
Day Low
0.0175
52W High
0.256
52W Low
0.0175
Volume
-
Avg. Volume
-
Mkt Cap
128,950.62
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 30Expected
Q4 2025
Q2 2026
-0.02
-0.01
-0.01
-0
Expected EPS
-0.0021728388388872
Actual EPS
-0.013097339909588

Financials

-535.02%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
8.67MRevenue
-46.37MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is ⁦0.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YP1B.MU. It's not an investment recommendation.
NVIDIA
15
NVDA
Amazon
11
AMZN
Alphabet
10
GOOGL
Palantir Technologies
10
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap356.01B
Merck & Co., Inc. competes with Immutep in the immuno-oncology space, particularly with their blockbuster drug Keytruda, which, like Immutep's lead candidate eftilagimod alpha, aims to enhance the immune system's ability to fight cancer.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb competes in the oncology and immuno-oncology sectors, offering drugs that directly compete with Immutep's pipeline by targeting similar pathways or mechanisms of action in cancer treatment.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, is involved in the development of immunotherapy treatments that compete with Immutep's products, especially in the field of cancer immunotherapy.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca PLC has a strong presence in the oncology sector, including immuno-oncology, with a portfolio that competes with Immutep's developments, particularly in combining therapies to enhance treatment efficacy.
Pfizer
PFE
Mkt Cap158.45B
Pfizer Inc. offers a range of oncology treatments, including immunotherapies that compete with Immutep's approach to cancer treatment, focusing on stimulating the immune system to attack cancer cells.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, Inc. competes with Immutep in the field of oncology and immuno-oncology, particularly with its focus on novel cancer therapies that could rival Immutep's product pipeline.
AMGEN
AMGN
Mkt Cap217.9B
Amgen Inc. has a diverse oncology portfolio, including immunotherapies that could compete with Immutep's efforts to modulate the immune system for cancer treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in oncology, including immuno-oncology, which could compete with Immutep's pipeline, especially in terms of novel mechanisms of action.
Novartis
NVS
Mkt Cap268B
Novartis AG has a strong focus on oncology and innovative cancer treatments, including immunotherapy, which positions it as a competitor to Immutep, especially in the development of new cancer treatment modalities.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its Janssen Pharmaceutical Companies, competes in the oncology space, including immunotherapy, with a broad range of products that could challenge Immutep's market position.

About

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Show More
CEO
Marc Voigt
Employees
51
Country
Australia
ISIN
AU000000IMM6
WKN
000A2H81H

Listings

MU
DE
YP1A.MU
STU
DE
YP1B.STU
F
DE
YP1.F
STU
DE
YP1A.STU

0 Comments

Share your thoughts

FAQs

What is Immutep Limited stock price today?▼
The current price of YP1B.MU is €0.02 EUR — it has decreased by -2.78% in the past 24 hours. Watch Immutep Limited stock price performance more closely on the chart.
What is Immutep Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Immutep Limited stocks are traded under the ticker YP1B.MU.
Is Immutep Limited stock price growing?▼
YP1B.MU stock has fallen by -2.78% compared to the previous week, the month change is a -32.69% fall, over the last year Immutep Limited has showed a -89.13% decrease.
What is Immutep Limited market cap?▼
Today Immutep Limited has the market capitalization of 128,950.62
When is the next Immutep Limited earnings date?▼
Immutep Limited is going to release the next earnings report on February 25, 2027.
What were Immutep Limited earnings last quarter?▼
YP1B.MU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was -0 EUR resulting in a -502.78% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Immutep Limited revenue for the last year?▼
Immutep Limited revenue for the last year amounts to 8.67M EUR.
What is Immutep Limited net income for the last year?▼
YP1B.MU net income for the last year is -46.37M EUR.
How many employees does Immutep Limited have?▼
As of October 27, 2026, the company has 51 employees.
In which sector is Immutep Limited located?▼
Immutep Limited operates in the Health & Wellness sector.
When did Immutep Limited complete a stock split?▼
The last stock split for Immutep Limited was on November 5, 2019 with a ratio of 1:10.
Where is Immutep Limited headquartered?▼
Immutep Limited is headquartered in Sydney, Australia.